|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||21.12 - 21.12|
|52-week range||18.14 - 21.71|
|Beta (3Y monthly)||0.53|
|PE ratio (TTM)||42.58|
|Forward dividend & yield||0.93 (4.44%)|
|1y target est||N/A|
Teva Pharmaceutical's UK unit has recalled some batches of heartburn medicine Ranitidine, Britain's medicines watchdog said on Thursday, making it the latest drugmaker to pull the product. Teva, the world's largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall. Teva did not immediately respond to a request for comment.
Glaxosmithkline (LON:GSK) is a global healthcare company that pays out an attractive rolling dividend yield of 4.75%. I'd like to know how safe Glaxosmithklin8230;
Why I think these steady FTSE 100 (INDEXFTSE: UKX) dividend-paying shares could power your compounding retirement savings.
The GSK share price offers the perfect combination of a steady dividend income and the potential for long-term growth, explains Rupert Hargreaves.
London's exporter-laden FTSE 100 lagged its European peers on Wednesday, as sterling gained on a report that the EU was ready to make a "major concession" on the Brexit divorce deal, while Just Eat helped the index hold on to slim gains. The blue-chip index, whose components make two-thirds of their earnings abroad, was slightly off the day's highs but was still up 0.1% by 0858 GMT, while the FTSE 250 was down 0.1%. Just Eat climbed 2% to top the FTSE 100 leader-board, after its Dutch rival Takeaway.com reported a surge in quarterly orders.
GlaxoSmithKline on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug. Zantac, also sold generically as ranitidine, is the latest drug in which cancer-causing impurities have been found. Britain's medicines watchdog said GlaxoSmithKline (GSK) was recalling four prescription-only Zantac medicines: a syrup, an injection and tablets of 150 and 300 milligram (mg) dosages.
Zantac, also sold generically as ranitidine, is the latest drug in which cancer-causing impurities have been found. Britain's medicines watchdog said GlaxoSmithKline (GSK) was recalling four prescription-only Zantac medicines: a syrup, an injection and tablets of 150 and 300 milligram (mg) dosages. Over-the-counter 75 mg dosage Zantac products are produced by a different company and are not affected by the recall, it added.
(Bloomberg) -- Three researchers from the U.S. and Britain won a Nobel Prize for showing how cells sense and adapt to changing oxygen levels, a line of research that’s already led to the development of new drugs.Americans William Kaelin of the Dana-Farber Cancer Institute in Boston and Gregg Semenza of Baltimore’s Johns Hopkins Medicine, and Peter Ratcliffe of the Francis Crick Institute in London received this year’s award for physiology or medicine, the Nobel Assembly at the Karolinska Institute said Monday in a statement.“The seminal discoveries by this year’s Nobel laureates revealed the mechanism for one of life’s most essential adaptive processes,” the assembly said in the statement. “Their discoveries have also paved the way for promising new strategies to fight anemia, cancer and many other diseases.”Semenza and Ratcliffe separately studied the processes surrounding the sensing of oxygen, and found it was at work in virtually all the body’s tissues. Semenza worked in the 1990s on identifying a protein complex that binds to cells’ DNA in response to levels of oxygen in the environment.The complex, called hypoxia inducible factor, regulates production of red blood cells. The science behind it is the basis for an anemia drug codeveloped by AstraZeneca Plc and Fibrogen Inc. called roxadustat that was approved in China in December.Astra is just a few steps away from bringing the drug to patients, said Mene Pangalos, executive vice president of biopharmaceutical research and development, in an email. “This would never have been possible without early breakthroughs of this year’s Nobel winners,” he said.GlaxoSmithKline Plc has filed for Japanese approval of a drug based on the mechanism, called daprodustat. Kaelin’s work linked the same oxygen-regulating machinery to a role in cancer, which is also being mined for potential therapeutics.Annual prizes for achievements in physics, chemistry, medicine, peace and literature were established in the will of Alfred Nobel, the Swedish inventor of dynamite, who died in 1896. The total amount for each of the 2019 prizes is 9 million kronor ($909,000).(Updates with company comment in sixth paragraph)\--With assistance from John Lauerman.To contact the reporters on this story: Niklas Magnusson in Stockholm at email@example.com;Veronica Ek in Stockholm at firstname.lastname@example.orgTo contact the editors responsible for this story: Jonas Bergman at email@example.com, ;Tasneem Hanfi Brögger at firstname.lastname@example.org, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Vectura Group said on Friday a British court had ruled in its favour on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline. Vectura said the court dismissed all GSK claims related to the packaging of AirFluSal Forspiro, which it developed in partnership with Sandoz, owned by Swiss drugmaker Novartis , as a branded version of GSK's asthma inhaler, Seretide Accuhaler.
Vectura said the court dismissed all GSK claims related to the packaging of AirFluSal Forspiro, which it developed in partnership with Sandoz, owned by Swiss drugmaker Novartis , as a branded version of GSK's asthma inhaler, Seretide Accuhaler.
A look at the shareholders of GlaxoSmithKline plc (LON:GSK) can tell us which group is most powerful. Large companies...
British drugmaker AstraZeneca said on Friday that the U.S. Food and Drug Administration (FDA) has approved self-administration of its asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen. The move is a boost for the drugmaker's respiratory portfolio after the regulator earlier this week declined to approve AstraZeneca's combination therapy to treat smoker's lung, as it tries to catch up with domestic rival GlaxoSmithKline. "We can now offer Fasenra in an even more convenient way, giving U.S. healthcare providers and patients the option of administering Fasenra at home or in a doctor's office," Mene Pangalos, executive vice president of BioPharmaceuticals R&D said.
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combination therapy to treat smoker's lung, the drugmaker said on Tuesday. AstraZeneca said that it will work closely with the FDA regarding next steps, including submitting results from an additional late-stage study, which was not completed at the time the marketing application was submitted to the health regulator. The therapy, PT010, was approved in Japan in June as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD), AstraZeneca said.
AstraZeneca presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease. The British drugmaker, together with development partner Merck & Co, said Lynparza was shown to delay disease progression in an aggressive and difficult-to-treat type of prostate cancer by a median 3.8 months in the group most sensitive to the treatment. The data, presented at the annual conference of the European Society for Medical Oncology (ESMO) in Barcelona, adds to further promising results presented on Saturday at the conference that may lead to wider use in women suffering from ovarian cancer.
Shares of AstraZeneca (LON: AZN) are priced for perfection, I believe. But does that make them a good buy for the long term?
* European shares tread water * STOXX 600 up 0.2% after slightly negative start * Volumes below average * JPM raises euro-zone stocks to "overweight" * ECB's Draghi emphasises need for fiscal push * Wall Street opens higher Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Josephine Mason. Reach her on Messenger to share your thoughts on market moves: rm://email@example.com AN UNEASY FEELING OF DEJA VU (1348 GMT) The markets are looking eerily similar to this time last year as Q4 approaches and Morgan Stanley's equity strategist Michael Wilson says he's got a feeling of deju vu.
* European shares tread water * STOXX 600 flat after slightly negative start * JPM raises euro-zone stocks to "overweight" * ECB's Draghi emphasises need for fiscal push * Asian shares mostly flat Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Josephine Mason. Reach her on Messenger to share your thoughts on market moves: rm://firstname.lastname@example.org MAKING THE CASE FOR A GERMAN FISCAL EXPANSION (1045 GMT) Goldman has weighed in on the debate about fiscal stimulus and while it agrees with a widespread view that a shock would be needed to convince Germany to open the purse strings, it argues that the case for Europe's No. 1 economy to do so is compelling.
European shares rose on Monday, with a higher open on Wall Street bolstering gains later in the session, while exporters were helped by a decline in the value of the euro. With Wall Street driven by a rally in iPhone maker Apple , investors seemed to shrug off fresh concerns about U.S.-China trade negotiations and looming U.S. tariffs on European imports.
UK shares were largely unchanged on Monday as investors opted for a wait-and-watch approach amid simmering U.S.-China trade tensions and Brexit worries, and as scant corporate news failed to spur significant stock moves. The exporter-heavy FTSE 100 index was roughly flat, but hovered close to a near two-month high, while the mid-cap index was also flat by 0800 GMT. The FTSE 100 index is on track for its best month since June and the domestically-focussed FTSE 250 was on course for its biggest monthly rise since April.
The exporter-heavy FTSE 100 index was roughly flat, but hovered close to a near two-month high, while the mid-cap index was also flat by 0800 GMT. The FTSE 100 index is on track for its best month since June and the domestically-focussed FTSE 250 was on course for its biggest monthly rise since April. GlaxoSmithKline added 1.5% after its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death, while AstraZeneca dipped 1.8% despite a positive reading of its ovarian cancer treatment.
Are you approaching retirement with an empty wallet? Royston Wild explains how you can still get rich before the time you hang up your work apron.